ERN1 and hematopoietic and lymphoid system neoplasm: Of type II kinase inhibitors of IRE1α, two compounds were selected for their potential utility in the therapy of blood cancers: N-{4-[(3-{2-[(trans-4-aminocyclohexyl)amino]pyrimidin-4-yl}yridine-2-yl)oxy]-3-methylnaphthalen-1-yl}-2-chlorobenzenesulfonamide (16) and (S)-2-chloro-N-(6-methyl-5-((3-(2-(piperidin-3-ylamino)pyrimidin-4-yl)yridine-2-yl)oxy)naphthalen-1-yl) benzenesulfonamide (18/KIRA8).